TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17006278
Drug: Injectable TIV
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable TIV (trivalent inactivated influenza vaccine)
Study: 17006278
Drug: Intranasal CAIV-T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal CAIV-T
Study: 17006278
Drug: Intranasal CAIV-T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal CAIV-T and Injectable TIV
Study: 9201603
Drug: Glutathione i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione i.v. administration (1 g/m2 bolus + 1 g/m2 in 2 h)
Study: 9201603
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test + glutathione administration
Study: 3426836
Drug: L-phenylalanine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-phenylalanine (high phe)
Study: 3426836
Drug: L-alanine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanine (low phe)
Study: 30002145
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg once daily, or 15 mg based on kidney function)
Study: 30002145
Drug: Warfarin (international
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (international normalized ratio target 2.5)
Study: 30002145
Drug: Rivaroxaban vs
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban vs Warfarin
Study: 22672058
Drug: Inulin 10
Normalized name: inulin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin 10 g
Study: 22672058
Drug: Inulin 20
Normalized name: inulin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin 20 g
Study: 22672058
Drug: SGF 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGF 40 g (acute consumption)
Study: 22672058
Drug: SGF 65
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGF 65 g (spread over the day)
Study: 17927795
Drug: ReCell treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReCell treatment
Study: 17186712
Drug: Oxybutynin (immediate-release)
Normalized name: oxybutynin Extended Release Oral Tablet
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin (immediate-release)
Study: 17186712
Drug: Tolterodine (immediate-release)
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolterodine (immediate-release)
Study: 17186712
Drug: Extended-release formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release formulations of Tolterodine or Oxybutynin
Study: 3082257
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (CS) pressurized aerosol, 1 mg per puff, 2 puffs, four times daily for 4 weeks
Study: 3082257
Drug: Placebo, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 puffs, four times daily for 4 weeks
Study: 31520633
Drug: Adjuvant Radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Radiation Therapy (RT)
Study: 31520633
Drug: No Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Adjuvant Radiation Therapy (RT)
Study: 27449925
Drug: Vitamin D3-enriched
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3-enriched Gouda-type cheese (60 g providing 5.7 μg of vitamin D3 daily)
Study: 26860022
Drug: I-GEL
Normalized name: Di-Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-GEL
Study: 23167912
Drug: M‐MIST with
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐MIST with rhPDGF‐BB gel
Study: 21296957
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (5.0 g daily, containing 2.0 g of EPA and 1.0 g of DHA)
Study: 21296957
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil (5.0 g of corn/soy mixture)
Study: 11374698
Drug: N2O/O2 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: N2O/O2 inhalation (50% N2O/O2)
Study: 8299548
Drug: Monoamine oxidase
Normalized name: Monoamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine oxidase inhibitor (MAOI) phenelzine
Study: 8299548
Drug: Tricyclic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic therapy
Study: 2936958
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or alternative treatment
Study: 31036033
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (moist hot pack, soft tissue mobilization, manual therapy, therapeutic exercise)
Study: 25926725
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g leucine/day plus resistance training (leucine group [LG], n=15)
Study: 12600870
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous amino acid solution (without glutamine)
Study: 1537959
Drug: Methylphenidate (35.21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (35.21 mg/day)
Study: 6726596
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplements from the 16th week of amenorrhea until 6 weeks post partum
Study: 29659116
Drug: DC0120 (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC0120 (5% minoxidil formulation), applied twice per day for 16 weeks
Study: 29659116
Drug: Comparator (ALOSTIL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (ALOSTIL® minoxidil product), applied twice per day for 16 weeks
Study: 29659116
Drug: DC0120 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC0120 and Comparator (both minoxidil treatments)
Study: 27572136
Drug: Intravenous methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methadone (0.1-0.125 mg/kg) in addition to standard care
Study: 21337116
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for 1 month
Study: 18614738
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 capsules of 1g providing 2.7g n-3 PUFAs per day)
Study: 18614738
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (4 capsules of 1g per day)
Study: 18614738
Drug: No oil
Normalized name: oregano oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oil capsules
Study: 10235530
Drug: IGF-1/IGFBP-3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-1/IGFBP-3 treatment at 1.0 mg/kg/day
Study: 10235530
Drug: IGF-1/IGFBP-3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-1/IGFBP-3 treatment at 2.0 mg/kg/day
Study: 10235530
Drug: IGF-1/IGFBP-3 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-1/IGFBP-3 treatment at 4.0 mg/kg/day
Study: 10235530
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IGF-1/IGFBP-3 treatment)
Study: 8904257
Drug: Vecuronium 0.056
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.056 mg/kg
Study: 8904257
Drug: Vecuronium 0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.14 mg/kg
Study: 8904257
Drug: Vecuronium 0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.28 mg/kg
Study: 8904257
Drug: Atracurium 0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.28 mg/kg
Study: 1824542
Drug: Casein formula
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein formula (1.4 gm protein/100 ml)
Study: 1824542
Drug: Supplemented human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemented human milk (1.4 gm protein/100 ml)
Study: 6405766
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride 0.4 mg with isobaric 0.5% bupivacaine
Study: 6405766
Drug: Morphine 0.2
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.2 mg (older patients only)
Study: 26297132
Drug: Ingested 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingested 0.3 g of raw salmon
Study: 26297132
Drug: Ingested 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingested 30 g of raw salmon
Study: 22595107
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL of 2% lidocaine with 1:200,000 epinephrine
Study: 22595107
Drug: 3.6 mL
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mL of 2% lidocaine with 1:200,000 epinephrine
Study: 15509514
Drug: AdvHSV‐tk gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdvHSV‐tk gene therapy (3 x 10(10) pfu) followed by intravenous ganciclovir (GCV), 5 mg/kg twice daily for 14 days
Study: 9322826
Drug: nifedipine-capsules (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine-capsules (10 mg)
Study: 9322826
Drug: captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (25 mg)
Study: 9322826
Drug: nifedipine-retard (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine-retard (20 mg)
Study: 31770598
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (APDT)
Study: 29049902
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment with Prolonged Exposure (COPE)
Study: 26769459
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg daily for 12 weeks
Study: 23442834
Drug: 72 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 72 weeks of treatment
Study: 23442834
Drug: 48 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 weeks of treatment
Study: 23442834
Drug: Stopping treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping treatment at week 12 for non-cEVR patients
Study: 23442834
Drug: Stopping treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping treatment at week 12 for cEVR patients
Study: 18647396
Drug: Remote therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote therapy (telephone, internet, videoconference)
Study: 16834839
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40 000 U weekly (QW)
Study: 10693734
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of orlistat TID
Study: 10693734
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of orlistat TID
Study: 9490144
Drug: Leuprolide 3.75
Normalized name: leuprolide 3.75 mg intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide 3.75 mg LP
Study: 9490144
Drug: Triptorelin 3.75
Normalized name: triptorelin 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 3.75 mg LP
Study: 3754233
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg bd + Pirenzepine 50 mg bd
Study: 3754233
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg bd
Study: 3754233
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg bd + Pirenzepine 25 mg bd
Study: 27342387
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of tedizolid phosphate (200mg)
Study: 27342387
Drug: Supratherapeutic dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic dose of tedizolid phosphate (1200mg)
Study: 12516414
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg three times a day for 7 days with tegafur 200 mg three times a day (Group I, n = 11)
Study: 12516414
Drug: Tegafur 200
Normalized name: tegafur 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur 200 mg three times a day without indomethacin (Group II, n = 10)
Study: 9098853
Drug: Allopurinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (10 mg/kg after meeting criteria and before cannulation, plus a 20 mg/kg priming dose to the ECMO circuit)
Study: 8210924
Drug: Etodolac (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (300 mg b.i.d.)
Study: 8210924
Drug: Active-reference preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-reference preparations (including piroxicam, naproxen, indomethacin, indomethacin SR, diclofenac SR)
Study: 8210924
Drug: Active-reference preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-reference preparations and placebos
Study: 3093661
Drug: Lactose-free preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-free preparation
Study: 28514624
Drug: Evacetrapib (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib (130 mg daily)
Study: 23135693
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tropisetron alone (T)
Study: 23135693
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tropisetron and 8 mg dexamethasone (TD)
Study: 23135693
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tropisetron and 40 mg methylprednisolone (TM)
Study: 21542721
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (300,000 IU/month intramuscular injection for 6 months)
Study: 21542721
Drug: Placebo (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscular injection for 6 months)
Study: 18498678
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 200 mcg once-daily for 8 days
Study: 17205817
Drug: Three-step sequential
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-step sequential method (TSSM) plus inhalation of Pulmicort Turbuhaler 200 microg, twice a day
Study: 8694043
Drug: Misoprostol every
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol every 3 hours (maximum of 8 doses)
Study: 8694043
Drug: Misoprostol every
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol every 6 hours (maximum of 4 doses)
Study: 27696720
Drug: FeFol (iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeFol (iron and folic acid tablet)
Study: 27696720
Drug: MMN (multiple-micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMN (multiple-micronutrients tablet)
Study: 27696720
Drug: PE (protein-energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE (protein-energy lipid-based nutritional supplement)
Study: 27696720
Drug: PE +
Normalized name: Chlorpheniramine Maleate/Phenylephrine Hydrochloride 4 MG-10 MG Oral Tablet [SINUS PE + ALLERGY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE + MMN (protein-energy + multiple-micronutrients lipid-based nutritional supplement)
Study: 25837705
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration (2 mg/kg testosterone enanthate monthly for two months before surgery)
Study: 17540191
Drug: Nurse-administered tailored
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered tailored behavioral intervention
Study: 17540191
Drug: Nurse-administered medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered medication management
Study: 17540191
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tailored behavioral intervention and medication management
Study: 11451215
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) 10 mg once daily
Study: 7747848
Drug: Propofol (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (median dose 3.1 mg.kg‐1)
Study: 7747848
Drug: Thiopentone (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (median dose 6.0 mg.kg‐1)
Study: 7747848
Drug: Intralipid 10%
Normalized name: Intralipid 10% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 10% 0.3 ml.kg‐1
Study: 299451
Drug: butorphanol/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: butorphanol/acetaminophen
Study: 299451
Drug: oxycodone/acetaminophen
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxycodone/acetaminophen
Study: 28376743
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg FLU-v in saline (arm 1)
Study: 28376743
Drug: Emulsified 500
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emulsified 500 μg FLU-v in Montanide ISA-51 and WFI followed by one saline dose (arm 2)
Study: 28376743
Drug: Montanide ISA-51
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montanide ISA-51 and WFI emulsion followed by one saline dose (arm 4)
Study: 28376743
Drug: Two saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two saline doses (arm 3)
Study: 25983095
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with docetaxel and capecitabine
Study: 20631375
Drug: Romiplostim 500
Normalized name: ROMIPLOSTIM 500MCG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim 500 μg
Study: 17952697
Drug: Water exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water exercise once-weekly for 24 weeks
Study: 17952697
Drug: Water exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water exercise twice-weekly for 24 weeks
Study: 15602503
Drug: Nalbuphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (5 mg/70 kg, intravenous)
Study: 15602503
Drug: Nalbuphine+cocaine (combination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine+cocaine (combination)
Study: 15602503
Drug: Cocaine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0.2 mg/kg, intravenous)
Study: 7700752
Drug: DTP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP and PRP-T in one injection (Group 1)
Study: 2505632
Drug: Flumazenil 4
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil 4 mg
Study: 24824770
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment + 6‐wk exercise (sports‐ADHD)
Study: 24824770
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment + 6‐wk education (edu‐ADHD)
Study: 23463297
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's Wort (SJW) 300 mg × 3/day for 2 weeks after PCI
Study: 20078381
Drug: 0.04% retinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04% retinol cream
Study: 16278692
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (PJ) supplementation (400 ml daily for 5 weeks)
Study: 16278692
Drug: Placebo (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (synthetic orange‐flavoured drink, 400 ml daily for 5 weeks)
Study: 11481130
Drug: Cognitive/Behavioral Therapy-Alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive/Behavioral Therapy-Alone (CBT)
Study: 9233238
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of essential fatty acids (EFA) - 20 ml solution A (1.6 gr EFA with linoleic acid, 112 UI vitamin A, 5 UI Vitamin E) applied every 8 hours for 21 days
Study: 9233238
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of mineral oil - 20 ml solution B (1.6 gr mineral oil, 112 UI Vitamin A, 5 UI Vitamin E) applied every 8 hours for 21 days
Study: 5320590
Drug: Chronic chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic chlorpromazine (CPZ) administration
Study: 30753377
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azathioprine with adalimumab
Study: 23128963
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen 10 mg/kg within 12‐24 h after birth followed by 5 mg/kg at 24 and 48 h
Study: 23128963
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ibuprofen treatment)
Study: 16965418
Drug: Placebo (cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cream base formulation)
Study: 19629020
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic medications
Study: 9240877
Drug: L-thyroxine (LT4)
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (LT4) replacement therapy
Study: 7506175
Drug: Nimesulide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (5 mg/kg/day)
Study: 7506175
Drug: Paracetamol (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (26 mg/kg/day)
Study: 30300371
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention (medication adjustment, stepped mental health care, exercise therapy)
Study: 28665259
Drug: Lenvatinib (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (24 mg/day; 28-day cycle)
Study: 26610844
Drug: Tafenoquine regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine regimen with three daily loading doses plus weekly maintenance at 200‐mg for 10 weeks or longer
Study: 26610844
Drug: Tafenoquine 200‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 200‐mg weekly